Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.

In this study, real-world data of 31 patients using ritlecitinib for severe alopecia areata showed that 51% achieved significant hair regrowth after one year, with no serious adverse events reported, emphasizing the importance of considering treatment duration for response.

This study found that normal human epidermis expresses TSH and may be an indirect target of TSH signaling, with expression regulated by endocrine controls of the hypothalamic-pituitary-thyroid axis.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study reports no new findings but provides corrected figures for the long-term safety and efficacy of ritlecitinib in treating alopecia areata from the ALLEGRO-LT phase 3 study.

In this study, researchers observed that twins with a novel de novo nonsense variant in HRAS exhibited distinctive features, including neuropsychiatric symptoms, potentially indicating a wider clinical spectrum for conditions known as RASopathies.

This study found that topical ruxolitinib protected Lgr5+ skin stem cells and maintained skin homeostasis in skin GVHD, unlike corticosteroids.

This review examines the potential of regulatory T cell-based therapies to transform treatment across various medical specialties by promoting immune tolerance and tissue repair, but it reports no new clinical results.

This study found that an optimal combination of ethnomedicinal extracts from East Nusa Tenggara, Indonesia, significantly increased hair length in mice, suggesting potential as a natural agent for hair growth through antioxidant mechanisms.

In this study, researchers using a Treg-specific HuR-deficient mouse model found that the RNA-binding protein HuR is crucial for stabilizing Foxp3 mRNA, affecting Treg function and immune regulation, with HuR disruption leading to impaired Foxp3 expression and potential autoimmune dysfunction.

This study showed that coexpression of TG2 and Gbx1 in the epidermis is necessary for esophagus-like mucosal transdifferentiation, with TGF-beta2 in the dermis essential for the process through epithelial-mesenchymal interaction.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

In a randomized, double-blinded, placebo-controlled clinical trial, this study found that the botanical-based compound ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.

An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.

This study observed that in spontaneously hypertensive rats, testosterone's effects on endothelium-dependent vasodilation involved reduced nitric oxide levels, increased oxidative stress, and greater reliance on endothelium-dependent hyperpolarization, with variations in these responses noted when testosterone was combined with either anastrozole or finasteride.

This report details a case of a 43-year-old woman developing yellowish papular eruptions alongside typical acneiform skin reactions on her cheeks and chest following a switch from cetuximab to panitumumab treatment.

This study found that patients with severe alopecia areata are willing to accept increased risks of serious infection, cancer, and blood clots when opting for a higher dose of ritlecitinib, valuing the potential for greater hair regrowth efficacy compared to a lower dose.

In this study, researchers developed a promising transdermal agent using Triton X-100-modified polyethyleneimine that successfully delivered genetic material to hair follicle cells in mice, potentially alleviating hair loss due to androgenetic alopecia by promoting cell proliferation and inhibiting apoptosis.

In this study, women with diffuse hair loss reported that Proteoglycan Replacement Therapy with Nourkrin® improved hair growth and appearance, boosting their confidence and satisfaction with the treatment.

In this study, researchers identified three root hair-specific peroxidases that may control cell wall properties during root hair cell expansion, affecting growth, enzyme activity, and cell wall structure.

In this retrospective cohort study, 53.8% of adult rosacea patients who started CGRP monoclonal antibodies for migraines experienced improvement in papules/pustules and erythema/flushing, although moderate adverse events were noted, suggesting these antibodies may benefit rosacea symptoms.

In this reported case, a 30-year-old man with a long history of alopecia universalis experienced limited regrowth of eyebrows and eyelashes after six months of deuruxolitinib, despite unchanged scalp hair, suggesting site-specific potential for hair regrowth in challenging cases.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

This study reported that a single treatment with a short-pulsed 755-nm alexandrite laser effectively treated trichostasis spinulosa in patients with skin types II to V, providing rapid results with minimal pain and no recurrence during a 3-month follow-up.

This study found that the synthetic thyroid hormone receptor modulator KB2115 significantly prolonged the growth phase of human hair follicles in culture without altering mitochondrial activity, suggesting potential as a safer hair loss treatment compared to traditional thyroid hormones.

In this article, the authors detail their experience with AltrenoTM, a new topical retinoid lotion used for treating mild to moderate acne, reporting clinical effectiveness and satisfactory tolerability among patients of various ages, including children as young as 9.